News

Revelation Biosciences Inc. Receives Invitation to give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

February 5, 2024

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

February 1, 2024

Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering

January 30, 2024

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

January 23, 2024

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

November 13, 2023

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023

October 12, 2023

Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies

October 4, 2023

Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference

October 2, 2023

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

August 11, 2023

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023

June 29, 2023

REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders

June 12, 2023

Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal

May 22, 2023

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress

March 30, 2023

Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress

March 13, 2023

Revelation Biosciences Inc. Appoints Dr. Julia Bohannon and Dr. Antonio Hernandez to Scientific Advisory Board

March 6, 2023

Revelation Biosciences Inc. to Participate in a Fireside Chat at the 35th Annual Roth Conference

February 13, 2023

Revelation Biosciences Inc. Announces Closing of $15.6 Million Public Offering

February 9, 2023

Revelation Biosciences Inc. Announces Pricing of $15.6 Million Public Offering

February 7, 2023

Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300

January 31, 2023

Revelation Biosciences Inc. Announces 1-for-35 Reverse Stock Split effective February 1, 2023 and Results of Special Meeting of Stockholders

January 10, 2023

Revelation Biosciences Inc. Announces Mandatory Unit Separation to Occur on January 13, 2023

November 18, 2022

Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model

November 10, 2022

Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress

October 25, 2022

Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease

October 6, 2022

Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement

August 15, 2022

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress

July 29, 2022

Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering

July 26, 2022

Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering

July 22, 2022

Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

July 14, 2022

Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

June 13, 2022

Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis

May 23, 2022

Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis

May 16, 2022

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress

April 6, 2022

Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update

March 30, 2022

Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99a for the Prevention of H3N2 Influenza Infection

March 24, 2022

Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx 99a for the Prevention of H3N2 Influenza Infection

March 22, 2022

Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC

March 15, 2022

Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx‑99 for the Prevention of H3N2 Influenza Infection

March 8, 2022

Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference

February 7, 2022

Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference

January 24, 2022

Revelation Biosciences Raises $7.76 Million in Equity Financing

January 20, 2022

Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza Infection

January 18, 2022

Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic Rhinitis

January 11, 2022

Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company

December 22, 2021

Petra Acquisition, Inc. Announces Share Redemption Backstop and Forward Purchase Agreements in Connection with Revelation Biosciences, Inc. Business Combination

December, 16, 2021

Petra Acquisition, Inc. Announces Special Meeting of Stockholders to Approve Business Combination with Revelation Biosciences, Inc.

December 6, 2021

Revelation Biosciences Inc. Appoints Joseph A. Bellanti, M.D. to Scientific Advisory Board

December 1, 2021

Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza

November 29, 2021

Revelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board

November 15, 2021

Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhinitis and Chronic Nasal Congestion

November 1, 2021

Revelation Biosciences Inc. Engages Partnering Advisor, MedWorld Advisors, to Optimize Value of the Company’s Diagnostic Tool, REVIDTM

October 25, 2021

Revelation Biosciences Inc. Engages Destum Partners Inc. to Identify a Strategic Partners for REVTx-99 (Ex-US) and REVTx-200 (Worldwide)

October 4, 2021

Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rhinitis and Chronic Nasal Congestion

September 28, 2021

Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx-99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections

August 30, 2021

Revelation Biosciences, Inc., a Life Sciences Company Developing Therapeutics and Diagnostics for Respiratory Viral Infections, Including COVID-19, to Become Publicly Traded through a Merger with Petra Acquisition, Inc.

June 9, 2021

Revelation Biosciences Inc. to Present at 2021 BIO Digital Conference

May 5, 2021

Revelation Biosciences Inc. Announces Results of Phase 1 Clinical Study of REVTx 99, an Experimental Therapy for the Prevention of Respiratory Viral Infection

February 11, 2021

Revelation Biosciences Inc. to Present at BIO CEO & Investor Digital Conference

February 2, 2021

Revelation Biosciences Inc. Completes Dosing of Five Single Dose Cohorts and Receives Approval to Initiate a Multiple Dose Cohort to Phase 1 Clinical Study of REVTx 99, an Experimental Treatment for Respiratory Viral Infection, Including COVID 19

February 1, 2021

Revelation Biosciences Inc. Announces Closing of $4.4 Million in Series A-1 Financing

January 11, 2021

Curt LaBelle, M.D. Appointed to Revelation Biosciences, Inc. Board of Directors

January 5, 2021

Revelation Biosciences Inc. Announces $9.1 Million Common Stock and Series A Financing

November 16, 2020

Revelation Biosciences Inc. Announces the Start of a Phase 1 Clinical Study for REVTx 99, an Experimental Treatment for Respiratory Viral Infection, Including COVID 19

October 15, 2020

Revelation Biosciences Inc. Appoints Jess Roper to Board of Directors

October 7, 2020

Revelation Biosciences Inc. Receives TGA Acknowledgment to Start a Phase 1 Clinical Study of REVTx‑99 an Experimental Treatment for COVID‑19

October 1, 2020

Revelation Biosciences Inc. Receives Approval to Start a Phase 1 Clinical Study of REVTx‑99 an Experimental Treatment for COVID‑19